Valve Replacement In Pediatric Patients Research Articles

Anisocytosis as a possible predictor of low cardiac output syndrome in children undergoing mitral valve surgery

PurposeMitral valve surgery in children involves correcting congenital and acquired pathologies, with a reported mortality rate of 0.9%. Low cardiac output syndrome (LCOS) is a serious complication with the incidence of 20–25%. The aim of the study was to estimate possible prognostic factors of LCOS in children undergoing mitral valve procedure. Material and methodThis single-center retrospective analysis enrolled children aged <18 years who underwent mitral valve surgery during 24 year period. Preoperative clinical and laboratory parameters, and operative factors were analyzed. ResultsThirty consecutive pediatric patients (11 (37%) males and 19 (63%) females) in median (Q1 – Q3) age of 57 (25–115) months, who underwent mitral valve replacement, were included. The 30-day mortality was 7% (2 patients) and was related to postoperative multiorgan failure. LCOS occurred in 8 (27%) children. The receiver operator curve (ROC) analysis established parameters that have predictive value for LCOS occurrence: cardiopulmonary bypass (CPB) time, with 89 ​min as optimal cut-off point (AUC ​= ​0.744, p ​= ​0.011) yielding sensitivity of 100% and specificity of 42.9%; left ventricular ejection fraction (LVEF) ​< ​60 % (AUC ​= ​0.824, okp ​= ​0.001) with sensitivity of 62.5% and specificity of 93.75%; and red blood cell distribution width (RDW) above 14.5 % (AUC ​= ​0.840, p ​< ​0.001; sensitivity of 87.5% and specificity of 75%). ConclusionsIn mitral valve replacement in pediatric patients, CPBtime above 89 ​min, preoperative LVEF below 60% and preoperative RDW above 14.5% can be regarded as the potential predictors of LCOS.

The Ross operation after removal of a transcatheter aortic valve replacement in pediatric patients.

The Ross operation after removal of a transcatheter aortic valve replacement in pediatric patients.

A roadmap to arrhythmias after transcatheter pulmonary valve replacement in pediatric patients.

Key Points In pediatric patients undergoing balloon‐expandable transcatheter pulmonary valve replacement within the native right ventricular outflow tract (RVOT), postprocedural ventricular arrhythmias were common and occurred in 33% of patients. Patients with postprocedural ventricular arrhythmias had a benign course, and all patients with follow‐up were successfully weaned off antiarrhythmic therapy. Patients with previous transannular patch repairs in the RVOT had an overall lower ventricular arrhythmia burden.

Aortic valve replacement in pediatric patients: 30 years single center experience

BackgroundThe choice of aortic valve replacement needs to be decided in an interdisciplinary approach and together with the patients and their families regarding the need for re-operation and risks accompanying anticoagulation. We report long-term outcomes after different AVR options.MethodsA chart review of patients aged < 18 years at time of surgery, who had undergone AVR from May 1985 until April 2020 was conducted. Contraindications for Ross procedure, which is performed since 1991 at the center were reviewed in the observed non-Ross AVR cohort. The study endpoints were compared between the mechanical AVR and the biological AVR cohort.ResultsFrom May 1985 to April 2020 fifty-five patients received sixty AVRs: 33 mechanical AVRs and 27 biological AVRs. In over half of the fifty-three AVRs performed after 1991 (58.5%; 31/53) a contraindication for Ross procedure was present. Early mortality was 5% (3/60). All early deaths occurred in patients aged < 1 year at time of surgery. Two late deaths occurred and survival was 94.5% ± 3.1% at 10 years and 86.4% ± 6.2% at 30 years. Freedom from aortic valve re-operation was higher (p < 0.001) in the mechanical AVR than in the biological AVR cohort with 95.2% ± 4.6% and 33.6% ± 13.4% freedom from re-operation at 10 years respectively.ConclusionsRe-operation was less frequent in the mechanical AVR cohort than in the biological AVR cohort. For mechanical AVR, the risk for thromboembolic and bleeding events was considerable with a composite linearized event rate per valve-year of 3.2%.

Application of transcatheter valves for aortic valve replacement in pediatric patients: A case series.

To describe our initial experience with pediatric transcatheter aortic valve replacement. Transcatheter aortic valve replacement (TAVR) has been approved and used to treat calcific aortic stenosis in adult patients. Select pediatric patients with congenital heart disease (CHD) who are poor candidates for conventional surgical aortic valve replacement can benefit from TAVR. A retrospective review was performed to identify and describe pediatric patients with CHD who underwent transcatheter or hybrid aortic valve replacement using a Melody Valve (Medtronic, Minneapolis, MN), or Sapien S3/XT valve (Edwards Life sciences LLC, Irvine, CA). Patients in whom transcatheter valves were implanted on cardiopulmonary bypass were included. Imaging data, procedural elements, and clinical follow-up data were collected to evaluate acute and short-term results. A total of eight pediatric patients underwent treatment of aortic valvular disease using balloon expandable valves and delivery systems. Two patients had Melody valve implantation and six received a Sapien valve (one XT/five S3). In one patient, a Melody valve was placed surgically, failed, and was replaced with a Sapien valve 2 years later. Two patients were treated using a standard transfemoral route, four had the valve delivered on cardiopulmonary bypass via a median sternotomy, one was placed with a transapical approach, and one via a carotid cut down. Patients were followed for an average 16 months (range 1-208 weeks). There were no early or late deaths in this cohort. There were no embolic events, and all valves worked well in the immediate postoperative period. Both Melody implants developed moderate to severe regurgitation at 2 years and 4 years, respectively, and both required replacement at that time. One Sapien 3 valve developed a paravalvular leak that required reintervention within 6 months of implantation. Transcatheter valves offer a reasonable alternative to traditional surgical aortic valve replacement in certain pediatric patients who are suboptimal surgical candidates. Hybrid approaches and valve delivery on cardiopulmonary bypass has been used in smaller patients. Long-term performance of these valves in young patients has not been studied.

Retrospective Comparison of the Supported and Unsupported Bovine Jugular Vein Conduit in Children

Bovine jugular vein (BJV) conduits are commonly used for pulmonary valve replacement in pediatric patients. They are available in supported (sBJV) and unsupported (uBJV) versions. The purpose of this study was to compare outcomes of sBJV and uBJV conduits. In this single-center retrospective review of patients younger than 18 years undergoing BJV placement (2009 to 2017), blinded cardiologists reviewed postoperative 6-, 12-, 24-, 36-month, and the most recent echocardiogram before any valve-related event or death. Outcomes assessed included conduit stenosis (m/s), regurgitation (none to mild vs moderate to severe) and right ventricular function (normal vs abnormal). Cox proportional models and Kaplan-Meier analyses were performed. BJV conduits (N= 109) were placed (39 supported, 70 unsupported) in 101 patients. Patient characteristics and conduit size were not different between cohorts. sBJV had more stenosis at 6 and 12 months (p= 0.02 and p= 0.03), but Vmax in both groups was mild (≤2 m/s). A greater proportion of uBJV had moderate to severe regurgitation at 12 months compared with sBJV (p= 0.03). Right ventricular function did not differ at any time point. On last follow-up echocardiogram, sBJV conduits had higher gradients (p= 0.01). This was not associated with increased intervention or replacement. Freedom from replacement or intervention did not differ between valve types (median follow-up, 3.6 years). There was a 9% incidence of endocarditis at median follow-up 2.4 years. Seventy percent of cases with endocarditis were managed medically. There were no clinically significant echocardiographic or outcome differences between sBJV and uBJV conduits. We identified a relatively high incidence of endocarditis, which is consistent with prior reports.

Surgical Atrioventricular Valve Replacement With Melody Valve in Infants and Children.

Background Pediatric patients with atrioventricular valve disease have limited options for prosthetic valve replacement in sizes <15 mm. Based on successful experience with the stented bovine jugular vein graft (Melody valve) in the right ventricular outflow tract, the prosthesis has been modified for surgical valve replacement in pediatric patients with atrioventricular dysfunction with the intention of subsequent valve expansion in the catheterization laboratory as the child grows. Methods and Results A multicenter, retrospective cohort study was performed among patients who underwent atrioventricular valve replacement with Melody valve at 17 participating sites from North America and Europe, including 68 patients with either mitral (n=59) or tricuspid (n=9) replacement at a median age of 8 months (range, 3 days to 13 years). The median size at implantation was 14 mm (range, 9-24 mm). Immediately postoperatively, the valve was competent with low gradients in all patients. Fifteen patients died; 3 patients underwent transplantation. Nineteen patients required reoperation for adverse outcomes, including valve explantation (n=16), left ventricular outflow tract obstruction (n=1), permanent pacemaker implantation (n=1), and paravalvular leak repair (n=1). Twenty-five patients underwent 41 episodes of catheter-based balloon expansion, exhibiting a significant decrease in median gradient ( P<0.001) with no significant increase in grade of regurgitation. Twelve months after implantation, cumulative incidence analysis indicated that 55% of the patients would be expected to be free from death, heart transplantation, structural valve deterioration, or valve replacement. Conclusions The Melody valve is a feasible option for surgical atrioventricular valve replacement in patients with hypoplastic annuli. The prosthesis shows acceptable short-term function and is amenable to catheter-based enlargement as the child grows. However, patients remain at risk for mortality and structural valve deterioration, despite adequate early valvular function. Device design and implantation techniques must be refined to reduce complications and extend durability. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT02505074.

Concept of an expandable cardiac valve for surgical implantation in infants and children

BackgroundOptions for cardiac valve replacement in children are limited to fixed-diameter prostheses that do not accommodate for somatic growth. An externally stented bovine jugular vein graft has been modified for surgical valve replacement in pediatric patients, with the intention of subsequent valve expansion in the catheterization laboratory as the child grows. MethodsPediatric patients at a single institution who underwent surgical implantation of an expandable bovine jugular vein valve between 2010 and 2014 were reviewed retrospectively. Forty-two patients underwent implantation at median age of 10 months (range, 3 weeks to 5.8 years) in aortic, mitral, pulmonary, or tricuspid positions. Numerous techniques for valve modification and implantation were used. ResultsThe valve was competent with low gradient acutely postoperatively in all patients. Eight patients experienced central or paravalvular deterioration, and 7 required reoperation for valve-related adverse outcomes. Twenty patients underwent at least one previous valve repair or replacement. Twenty patients underwent 32 episodes of catheter-based balloon expansion of the valve, exhibiting a significant decrease in median gradient from 12 mm Hg to 8 mm Hg (P < .001) with no significant increase in grade of regurgitation. At 12 months after implantation, Kaplan-Meier analysis indicated that 88% would be expected to be free from reoperation (95% confidence interval, 78%-98%). A total of 6 deaths occurred, 3 before discharge and 3 late. ConclusionsA surgically implanted externally reinforced bovine jugular vein demonstrates acceptable short-term function and is amenable to catheter-based enlargement as the child grows. Modification of valve design and implantation techniques are necessary to reduce perivalvular complications.

Predictors of Left Ventricular Remodeling after Aortic Valve Replacement in Pediatric Patients with Isolated Aortic Regurgitation

To identify the risk factors that could predict postoperative outcome after aortic valve replacement in pediatric patients with isolated aortic regurgitation (AR). There is controversy regarding the appropriate timing of surgery in asymptomatic or minimally symptomatic patients with isolated AR. In the pediatric age group, there are limited studies in this regard and most of them are on combined aortic valve stenosis and regurgitation. All patients with biventricular physiology and morphologic left ventricle (LV) who underwent aortic valve surgery for AR from January 1988 to July 2010 were included in the study. Demographic, clinical, and echocardiographic data were collected at presurgical visit, early postoperative, 1 year, and most recent follow-up. Among 53 patients (36 males), 18 had LV end-diastolic diameter (LVEDD) z-score >4 standard deviation (SD) (group I) and 35 had LVEDD <4 SD (group II). Forty-one had long-term follow-up. Mean age at surgery was 11.6 ± 5.9 years; mean follow-up was 6.9 ± 5.6 years. Preoperative LVEDD >4 SD predicted persistent LV dilation (>2 SD) at early post-op (P < .05) and 1 year follow-up (P = .09). Preoperative decreased LV function (fractional shortening <28%) was the only significant predictor of persistent LV dysfunction at most recent follow-up and requirement for repeat interventions (P < .01). Most have reduction of LV dimensions in the immediate postoperative period to normal limits. In children with AR, preoperative LV dysfunction and extreme LV dilation (>4 SD) are significant predictors of incomplete LV remodeling or persistent LV dysfunction.

Homograft Performance in Children After the Ross Operation

The Ross operation may be the ideal aortic valve replacement in pediatric patients. However, reoperations for replacement of the homograft in the pulmonary position are inevitable. This study determined influencing factors for the development of homograft stenosis and regurgitation in pediatric Ross patients. Follow-up echocardiograms of 116 children (86 boys) undergoing Ross operations at a mean age, 9.3 +/- 4.9 years were analyzed using hierarchic multilevel modeling. Mean duration of the echocardiographic follow-up was 5.3 +/- 4.2 years (609 patient-years, 398 examinations). Median homograft diameter z value was 0.3 (range -2.2 to +7.3). Mean homograft pressure gradient at implantation was 5.0 mm Hg with a significant increase of 4.2 mm Hg/y (p < 0.001) within the first 2 years and a steady state thereafter. Older donor age was significantly associated with lower mean pressure gradient at implantation (p = 0.037). Larger z value had no significant influence on the annual increase of pressure gradient (p = 0.87). Mean grade of regurgitation at implantation was 0.9, without significant annual increase (0.02 grade/y, (p = = 0.32). Older recipient (p = 0.005) and donor age (p < 0.0001) were significantly associated with lower mean regurgitation at implantation. Larger z value was associated with a higher annual increase of regurgitation (p = 0.014). Relevant midterm homograft regurgitation is rare in children after the Ross operation. However, a significant annual increase occurs in the pressure gradient that cannot be influenced by larger graft size. Homograft oversizing may lead to a higher annual increase of regurgitation.

Homograft performance in 84 pediatric Ross patients – results from the Dutch-German Ross registry

Aims: The Ross operation may be the ideal aortic valve replacement in pediatric patients. However, reoperations for replacement of the homograft (HG) in the pulmonary position are inevitable. This study was conducted to determine influencing factors for the development of homograft stenosis (HS) and regurgitation (HR) in an international pediatric Ross operated cohort.

Mechanical Aortic and Mitral Valve Replacement in Infants and Children

The aim of this study was to evaluate early and late outcomes after mechanical systemic heart valve replacement in pediatric patients. Between October 1981 and December 2003, 32 children (mean age 7.2 +/- 5.4 years; 4 months - 15.9 years) underwent mechanical mitral (MVR, n = 17), aortic (AVR, n = 13) or double valve replacement (DVR, n = 2) with St. Jude Medical valves. Twenty-two patients (69 %) had undergone previous cardiac surgery. Anticoagulation self-management was used since 1995. The operative mortality was 3.1 %. Perioperative complications were complete heart block (n = 5), ventricular fibrillation (n = 1) and myocardial infarction (n = 1) and were exclusively related to patients with MVR. Mean calculated valve size ratio (geometric prosthesis orifice area/normal valve size area) was 1.72 (1.07 - 2.85) for AVR and 1.4 (0.88 - 3.12) for MVR. Mean follow-up was 9.1 +/- 6.6 years (range 0.4 - 23.2 years, cumulative 283 patient-years). There were two late deaths in patients with MVR. Actuarial survival after 10 years was 93.8 %. Late complications were endocarditis (n = 2), minor hemorrhagic event (n = 1), and stroke (n = 1). Anticoagulation self-management is well accepted by all patients/parents. Overall 10-year freedom from any anticoagulation-related adverse event with phenprocoumon was 89.1 % (1.2 %/patient year). Nine patients required reoperations: redo-MVR (outgrowth of prostheses (n = 3), pannus overgrowth (n = 2), closure of paravalvular leak after AVR (n = 2), partial aortic valve thrombosis (n = 1) and redo-DVR (n = 1 for endocarditis). Freedom from reoperation after 10 years was 80.9 %. Mechanical valve prostheses are a valuable option for left-sided heart valve replacement in pediatric patients. Perioperative morbidity was exclusively related to patients with MVR. Oversizing was often possible to avoid early reoperation for outgrowth. The operative mortality and long-term morbidity are acceptable. Anticoagulation self-management is safe and well accepted.

Systemic mechanical heart valve replacement in children under 16 years of age

We report the early and late outcome following left-sided mechanical heart valve replacement in children. Between 10/1981 and 02/2001, 27 children (13 male, mean age 7.2 +/- 5.2 years, range 0.53-15.7 years) underwent mechanical mitral (MVR 16), aortic (AVR 9) or double valve replacement (DVR 2) with St. Jude Medical valves. Eighteen children (66.7%) had undergone previous cardiac surgery. Valve disease was congenital in 23, due to endocarditis in 2 and rheumatic in 2 patients. Concomitant cardiac surgery was performed in 12 patients (44.4%). Operative mortality was 3.7% (1/27). Perioperative complications were complete heart block (5) and myocardial infarction (1). Mean follow-up was 6.5+/-5.9 years (range 0.4-19 years, total 169.9 patient-years). There was one valve-related late death due to mitral valve thrombosis without phenprocoumon. Actuarial survival after 1, 5 and 10 years was 93, 93 and 93%. Late complications included endocarditis (2), minor hemorrhagic event (1) and stroke (1). Overall 10-year freedom from any anticoagulation-related adverse event under phenprocoumon was 91% (1.3%/patient year). Eight patients required reoperations: re-MVR (5; outgrowth of the prostheses (3), pannus overgrowth (2)), closure of paravalvular leak after AVR (2), and re- DVR (1; endocarditis). Actuarial freedom from reoperation after 1, 5 and 10 years was 96, 88 and 76%. Mechanical valve prostheses are a valuable option for left-sided heart valve replacement in pediatric patients with good results. Operative mortality and the incidence of any valve-related events as endocarditis, reoperation, thromboembolism or anticoagulation related bleeding is acceptable.

Hemodynamic and Electrocardiographic Effects of Early Pulmonary Valve Replacement in Pediatric Patients After Transannular Complete Repair of Tetralogy of Fallot

In adults, pulmonary value replacement (PVR) shows improvement in right ventricular (RV) volume and function and reduces QRS duration. In addition, RV volume correlates with QRS duration and QRS change. This has not been shown in pediatric patients. The purpose of this study was to evaluate serial magnetic resonance imaging (MRI) and electrocardiogram measurements before and after early PVR in a pediatric population with repaired Tetralogy of Fallot and whether QRS duration and QRS change correlated with RV volume. A retrospective review of MRIs and electrocardiograms was conducted on 10 patients. Median age at repair was 2.1 +/- 0.7 years, and median age at PVR was 11.5 +/- 2.0 years. There were significant decreases in RV end diastolic volume (EDV)/body surface area (BSA) (p < 0.0004), end systolic volume (ESV)/BSA (p = 0.02), RVEDV/left ventricular (LV) EDV (p < 0.001), RV ejection fraction (p < 0.04), RV stroke volume (SV)/BSA (p < 0.0002), and (RVSV - LVSV)/BSA (p = 0.0007). No significant change in QRS duration occurred (p = 0.08). QRS duration (pre-r = 0.44, p = 0.20; post-r = 0.34, p = 0.33) and QRS change (r = -0.08, p = 0.83) did not correlate with RVEDV. We propose early consideration of PVR in pediatric patients. PVR improves RV volumes and function and may provide beneficial electromechanical effects by slowing the progression of QRS duration.

Defining biomechanical endpoints for tissue engineered heart valve leaflets from native leaflet properties

The design and development of functional engineered tissues is dependent on multiple considerations, with biomechanics paramount for load-bearing constructs such as tissue engineered heart valves. As the cryopreserved allograft is the current standard for valve replacement in pediatric patients, identifying and quantifying essential structural–mechanical properties of the native valve leaflet is a crucial step in the engineered valve leaflet design process. Native valve leaflet properties provide an intuitive basis for assessing engineered valvular tissue performance, and can potentially be used as biomechanical endpoints for qualifying engineered leaflets prior to clinical applications. In this short review, we present three analysis techniques that have been used by our lab and others for characterizing heart valve leaflet biomechanical response and discuss the relevance of these properties as candidate endpoints for engineered leaflet tissues. The studies presented herein focused primarily on the aortic valve, which most frequently warrants repair or replacement in the general population and has been useful in our understanding of bioprosthetic heart valve mechanics. However, these analysis techniques are directly applicable for pulmonary and most engineered valve leaflets. Where data is available, initial studies applying these techniques for in vitro assessment of scaffolds and engineered valve leaflets are presented. The development of a tissue engineered heart valve for the pediatric population is conceptually appealing, since few options currently exist due to the lack of growth potential in non-viable prosthetics and size limitations. While significant challenges remain, we believe that a derivative of the current tissue engineered heart valve paradigm will ultimately yield a design suitable for clinical evaluation. The role of biomechanics in this process will be to identify and quantify the structural–mechanical endpoints essential for appropriate heart valve leaflet function, while guiding investigators prior to and during clinical evaluation.

Left-sided mechanical heart valve replacement in pediatric patients

Introduction: Left-sided mechanical heart valve replacement in pediatric patients is generally considered a problem. We report on early and late outcome after aortic and/or mitral mechanical heart valve replacement.

Freedom from aortic valve replacement in pediatric patients with congenital aortic stenosis after initial balloon valvuloplasty versus operative commissurotomy

Aims: Aortic stenosis (AS) in pediatric patients is treated initially with either balloon valvuloplasty (BV) or operative commissurotomy (OC). The objective was to compare freedom from aortic valve replacement (AVR) after the two treatments.

Prosthetic valve replacement in pediatric patients: analysis of 105 cases

To summarize the experience in prosthetic valve replacement in pediatric patients. The clinical data of consecutive 105 children, 63 male and 42 female, aged 13 +/- 3 (1.5-16), with the underlying diseases of rheumatic heart disease (n = 55), congenital heart diseases (n = 43), and infective endocarditis (n = 5), with the preoperative cardiac function of class II (n = 36), or class III or IV (n = 69), who underwent prosthetic valve replacement, including replacement of mitral valve (n = 58), aortic valve (n = 28), tricuspid valve (n = 5), mitral and aortic valves (n = 13), and mitral and tricuspid valves (n = 1), and tricuspid valvuloplasty (n = 26), from May 1984 to May 2004, were respectively analyzed. Mechanical valves were used and took low dose anticoagulant warfarin was administrated to all cases. Postoperatively prothrombin time (PT) and international normal ratio (INR) were observed. Follow-up lasting 10 +/- 4 years (6 months to 20 years) was performed among 100 discharged patients with a follow-up rate of 91.0%. There were 5 early deaths (4.8%), mostly owing to serious low cardiac output syndrome, and 4 late deaths owing to endocarditis (n = 2), heart failure (n = 1), and serious arrhythmia (n = 1). The 87 surviving patients showed their cardiac function of class I-III. No serious complications related to anticoagulation and prosthesis dysfunction had been found. Prosthetic valve replacement with mechanical valve can be performed in pediatric patients with good outcome. Larger type of mechanical valve should be used as possible. Additional surgical procedures may be required to correct the concomitant malformations during the operation. Postoperative long-term low dose anticoagulant treatment is safe.

Right ventricular outflow tract reconstruction with the Contegra bovine jugular vein conduit: a word of caution

Background Since introduction in 1999, pulmonary valve replacement in pediatric patients with the Contegra conduit (Medtronic Inc, Minneapolis, MN) has gained widespread application with increasing enthusiasm. However, unexpected graft related adverse effects may occur. Methods Between April 2001 and December 2002, 29 patients (20 male; mean age, 3.39 ± 3.66 years; range, 0.01 to 13.0 years; mean weight, 11.62 ± 8.73 kg) underwent right ventricular outflow tract reconstruction with the Contegra conduit. Seventeen patients underwent primary repair, 8 had prior homografts, and 4 had other previous operations. Results There were no deaths. Three early graft related complications were observed. In two infants (age, 1.8 and 3.5 months; weight, 3.6 and 3.8 kg, respectively) thrombus formation at the conduit valve was detected 2 weeks postoperatively. Under anticoagulation with low-molecular-weight heparin, thrombi resolved completely in both patients. One patient (4.5 months, 4.43 kg) developed severe regurgitation due to a fibrous layer covering the inner conduit wall and required conduit exchange 3 weeks postoperatively. After a mean follow-up time of 10.2 ± 6.4 months all patients are in good clinical condition. However, one patient with systemic right ventricular pressure developed pseudoaneurysm at both graft insertion sites and is scheduled for reoperation. Two other patients underwent balloon dilation. Freedom from reoperation and intervention at 1 year is 89.4%. With regard to regurgitation and conduit stenosis all other conduits perform well. Conclusions Contegra conduits are an alternative to homografts for right ventricular outflow tract reconstruction. However, there is a risk of thrombus formation in small infants so that prophylactic anticoagulation may be necessary. Patients with systemic right ventricular pressure require close observation as pseudoaneurysm formation has been observed.

Pericardial Leaflet Extension for Aortic Valve Repair: Techniques and Late Results

A modified technique to repair aortic valve is described. The technique consists of tailored extension of the old valve leaflets with gluteraldehyde treated autologous pericardium. The technique has excellent intermediate results and is an alternative to valve replacement in pediatric patients. Copyright 1999 by W.B. Saunders Company